Home›Stock Screener›Novartis

Novartis Share Price Today | Stock Price & Novartis Share Screener

NOVARTIND Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1717.70
▲ 25.30 (1.49%)
2026-11-02 00:00:00
Live Share Price BSE
₹1718.35
▲ 24.50 (1.45%)
2026-11-02 00:00:00

As of November 2, 2026, the live Novartis share price (NSE: NOVARTIND) is ₹1,717.70 on NSE and ₹1,718.35 on BSE, up 1.49% from the previous close, with shares trading between ₹1,693.30 and ₹1,799.60 in today's trading session, and a 52-week range of ₹962.00–₹2,428.20. Track NOVARTIND market cap trends to gauge the company's total market size. Use the Novartis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Novartis opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹408 and net income of ₹98, with EBITDA of ₹139, an operating margin of 27.0% and a profit margin of 24.0%.

Novartis Market Cap ₹4,178.67 Cr.
NOVARTIND P/E Ratio (TTM) 45.80
Novartis P/B Ratio 5.47
EPS (TTM) ₹37.74
Dividend Yield 1.38%
Debt to Equity 0.01
NOVARTIND 52 Week High ₹2428.20
Novartis 52 Week Low ₹962.00
Operating Margin 27.00%
Profit Margin 24.02%
NOVARTIND Revenue (TTM) ₹408.00
EBITDA ₹139.00
Net Income ₹98.00
Total Assets ₹978.00
Total Equity ₹818.00

Novartis Share Price Chart

Track the current stock price of Novartis with an interactive chart. Analyse NOVARTIND share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Novartis stock quote in one place.

The quote of ₹1,717.70 sits between the 52-week low of ₹962.00 and the 52-week high of ₹2,428.20, and the latest session moved 1.49% from the previous close.

Novartis Company Profile - Fundamental Screener

Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NOVARTIND shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE234A01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE234A01025

Novartis Balance Sheet Screener

Screen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹978, up from ₹948 in 2025.

Latest statistics put total assets at ₹978 and shareholder funds at ₹818, with a leverage ratio of 0.01.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 978 948 925 983 958 1,002 1,078 982 1,111 1,150
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 3 5 7 19 24 64 76 15 5 6

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 16 21 23 48 50 132 124 38 47 47
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 818 785 745 776 692 711 721 759 734 920
Share Capital 12 12 12 12 12 12 12 12 12 14
Reserves & Surplus 806 773 733 763 679 699 708 747 721 906

Novartis Income Statement Screener - Profit & Revenue Analysis

Screen Novartis income statement and profit fundamentals. Analyze NOVARTIND quarterly results. Novartis reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹408 and net profit was ₹98, equal to earnings per unit of ₹39.60, at an operating margin of 27%.

In that period expenses were ₹269, interest cost ₹1 and tax ₹37. The next period listed, 2026-March, shows revenue of ₹393 and net profit of ₹93.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 408 393 398 397 437 433 414 474 569 736 727 771 981
Expenses 269 260 265 270 314 373 355 426 478 570 631 656 877

Operating Costs and Margins

EBITDA 139 133 133 127 123 60 60 48 91 166 96 115 104
Operating Profit % 27.00% 27.00% 26.00% 19.00% 17.00% 7.00% 7.00% 3.00% 3.00% -1.00% 4.00% 5.00% 0.00%
Depreciation 2 2 2 3 6 10 12 13 3 3 4 4 4
Interest 1 1 1 2 2 5 8 6 2 6 1 0 0

Profit and Earnings

Profit Before Tax 136 130 130 123 115 -4 40 29 86 158 92 111 93
Tax 37 37 30 38 12 0 19 19 34 79 35 39 14
Net Profit 98 93 101 85 103 -4 21 10 52 78 57 73 79
EPS 39.60 37.74 40.87 34.50 41.86 -1.51 8.46 4.08 20.97 28.43 19.10 62.04 24.75

Novartis Cash Flow Screener - Liquidity Fundamentals

Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹47.

Over the same period, investing activities provided ₹18 and financing activities used ₹64.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 47 75 113 45 39 -69 -23 -194 161 -41
Investing Activities 18 -3 33 -153 87 95 56 274 69 424

Financing and Net Cash

Financing Activities -64 -64 -121 -31 -36 -37 -41 -30 -268 -332
Net Cash Flow 0 7 26 -139 90 -11 -9 50 -38 51

Novartis Shareholding Pattern Screener

See Novartis shareholding pattern with promoter, FII, and DII holdings. Check Novartis promoter holding and ownership changes for NOVARTIND on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 70.68%, foreign institutions 0.17%, domestic institutions 0.53% and the public 23.25%, spread across 38,116 shareholders.

The shareholder count was 38,116 in 2026-Mar, compared with 36,502 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Jul 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68%

Institutional Investors

FII Holding 0.17% 0.16% 0.15% 1.22% 0.19% 0.19% 0.19% 0.19%
DII Holding 0.53% 1.36% 1.39% 1.50% 0.53% 0.53% 0.53% 0.64%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.25% 22.50% 22.43% 21.29% 23.11% 22.95% 22.92% 22.67%
Other Holding 5.36% 5.31% 5.35% 5.31% 5.49% 5.66% 5.68% 5.83%
Shareholder Count 38,116 36,502 36,706 38,127 39,133 39,040 39,353 39,468

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Novartis. Novartis dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹25.00 per unit for 2026-March, a yield of 1.48%, compared with ₹25.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹25.00, ₹25.00 and ₹25.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹25.00 1.48%
2025-March ₹25.00 2.58%
2024-March ₹25.00 3.18%
2023-March ₹47.50 7.07%
2022-March ₹10.00 1.77%
2021-March ₹10.00 1.70%
2020-March ₹10.00 1.81%
2019-March ₹10.00 1.99%
2018-March ₹10.00 1.46%
2017-March ₹10.00 1.63%

Novartis Stock Index Membership - Nifty & Sensex

See which indices include Novartis stock. Check NOVARTIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Novartis Market Events Screener - Corporate Actions

Get Novartis corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Novartis stock events that may affect NOVARTIND share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.

It is followed by Annual General Meeting dated September 24, 2026 and Quarterly Result Announcement dated July 23, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-03 2026-11-03 Quarterly Result Announcement NA -11.97%
2026-09-24 2026-09-24 Annual General Meeting NA 26.59%
2026-07-23 2026-07-23 Quarterly Result Announcement NA 16.63%
2026-05-12 2026-05-12 Quarterly Result Announcement NA 21.81%
2026-01-28 2026-01-28 Quarterly Result Announcement NA 3.23%
2025-10-28 2025-10-28 Quarterly Result Announcement NA -3.77%
2025-07-31 2025-07-31 Annual General Meeting NA 24.87%
2025-07-29 2025-07-29 Quarterly Result Announcement NA -0.92%
2025-07-23 2025-07-23 Dividend ₹ 25.00 /share 33.11%
2025-05-09 2025-05-09 Quarterly Result Announcement NA -3.94%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -4.09%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -9.21%
2024-07-31 2024-07-31 Annual General Meeting NA 11.66%
2024-07-23 2024-07-24 Dividend ₹ 25.00 /share 5.99%
2023-07-20 2023-07-21 Dividend ₹ 10.00 /share 32.63%

Novartis Competitors Screener - Peer Stocks Comparison

Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 426,530 34.90 61,674 12.69% 11,565 47.71
Divis Laboratories 259,628 87.60 11,067 13.95% 2,568 64.36
Torrent Pharmaceuticals 175,479 82.70 13,886 20.34% 2,138 44.74
Laurus Labs 129,972 111.30 6,868 22.01% 890 78.71
Zydus Life Science 124,239 25.80 27,658 17.64% 5,026 70.87
Dr Reddys Laboratories 112,849 40.50 35,059 3.90% 4,158 75.33
Cipla 111,396 38.40 29,045 2.24% 3,870 59.16
Mankind Pharma 102,964 44.90 14,636 14.85% 1,938 58.49
Aurobindo Pharma 96,744 25.70 34,145 5.56% 3,503 54.82
Lupin 91,961 16.50 29,039 26.75% 5,356 51.38

Novartis Company Announcements - News & Reports Screener

Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 30, 2026.

The next most recent announcements are dated October 30, 2026 and October 14, 2026.

Date Update Actions
2026-10-30 Intimation Of The Earnings Call Proposed To Be Held On November 04 2026 At 02:30 PM IST -
2026-10-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-13 Notice Of Postal Ballot (02/2026-27) - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Of Evonile Pharma Limited (Formerly Known As Novar -
2026-10-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-08 Announcement under Regulation 30 (LODR)-Raising of Funds -
2026-10-08 Announcement under Regulation 30 (LODR)-Issue of Securities -
2026-10-08 Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Held Today Dated October 08 2026 -
2026-10-07 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-10-05 Board Meeting Intimation for Consideration Of Raising Of Funds Through The Issuance Of Equity Shares Of The Company. -
2026-10-01 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2026-10-01 Announcement under Regulation 30 (LODR)-Change of Company Name -
2026-09-30 Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. -
2026-09-30 Closure of Trading Window -
2026-09-25 Intimation Of The Voting Results And The Scrutinizers Report For The 78Th Annual General Meeting Of The Company Held On Thursday September 24 2026. -
2026-09-24 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-23 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-21 Intimation Regarding The Newspaper Publication Made Regarding The Corrigendum Filed Dated September 18 2026 For The Notice Of 78Th Annual General Meeting -
2026-09-18 Corrigendum To The Notice Of 78Th Annual General Meeting -
2026-09-15 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,717.70, within a 52-week range of ₹962.00 to ₹2,428.20. The P/E ratio is 45.80 and the P/B ratio is 5.47, with earnings per unit of ₹37.74. Market capitalisation stands at ₹4,178.67 Cr and the dividend yield is 1.38%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 4, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.